



Array BioPharma To Report Financial Results For The First Quarter Of Fiscal 2018 On October 31, 2017

October 24, 2017

BOULDER, Colo., Oct. 24, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, October 31, 2017. Ron Squarer, Chief Executive Officer, will lead the call.

Date: Tuesday, October 31, 2017
Time: 9:00 a.m. Eastern Time
Toll-Free: (844) 464-3927
Toll: (765) 507-2598
Pass Code: 94698561



Webcast, including Replay and Conference Call Slides:

<https://edge.media-server.com/m6/p/hcxcet4b>

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

CONTACT: Tricia Haugeto
Array BioPharma Inc.
(303) 386-1193
thaugeto@arraybiopharma.com

View original content with multimedia: <http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-first-quarter-of-fiscal-2018-on-october-31-2017-300541497.html>

SOURCE Array BioPharma Inc.